Nasal Vaccination Against SARS-CoV-2: Synergistic or Alternative to Intramuscular Vaccines?
Mattia Tiboni, Luca Casettari, Lisbeth Illum It is striking that all marketed SARS-CoV-2 vaccines are developed for intramuscular administration designed to produce humoral and cell mediated immune responses, preventing viremia and the COVID-19 syndrome. They have a high degree of efficacy in humans (70–95%) depending on the type of vaccine. However, little protection is provided […]
Pharma Eyes Big Profits in Nasal Vaccines – Should We Really Spray Nanoparticles So Close to the Brain?
The Defender Staff Vaccine manufacturers set their sights on nasal vaccines at least two decades ago, but so far product development has remained sluggish as scientists acknowledge that only a “thin partition” separates the nasal cavity from the brain. … Would nasal sprays be more benign than their injectable counterparts? Experience thus far urges caution. […]
